Herantis Pharma Oyj (HEL:HRTIS)
Finland · Delayed Price · Currency is EUR | Market Cap | 42.94M +1.2% |
| Revenue (ttm) | n/a |
| Net Income | -6.74M |
| EPS | -0.27 |
| Shares Out | 26.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,369 |
| Open | 1.658 |
| Previous Close | 1.620 |
| Day's Range | 1.648 - 1.696 |
| 52-Week Range | 1.440 - 3.870 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland. [Read more]
Financial Performance
Financial StatementsNews
Herantis Pharma Oyj Earnings Call Transcript: H1 2026
HER-096 is advancing to a phase II trial in early-stage Parkinson's, supported by strong phase I data, an €8M EU grant, and positive FDA feedback. The company maintains a focused pipeline, stable costs, and is seeking additional funding to support the €20M trial.
Herantis Pharma Oyj Quarterly report: H1 2026
Herantis Pharma Oyj has published its H1 2026 quarterly earnings report on August 20, 2026.
Herantis Pharma Oyj Slides: H1 2026
Herantis Pharma Oyj has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 20, 2026.
Herantis Pharma Oyj Slides: Company presentation
Herantis Pharma Oyj has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
Herantis Pharma Oyj Transcript: Study update
HER-096 is set for a phase II-A trial in early-stage Parkinson's, using a digital motor score as the primary endpoint to enhance sensitivity and objectivity. Over half of the funding is secured, and regulatory feedback has been positive, with a focus on innovative digital health technology.
Herantis Pharma Oyj Press release: Study update
Herantis Pharma Oyj issued a press release on June 2, 2026, disclosing material business information to investors.
Herantis Pharma Oyj Earnings Call Transcript: H2 2025
HER-096 advanced through phase 1b with strong safety, brain penetration, and biomarker results, positioning for a phase two efficacy trial in Parkinson's disease. Financial position improved with grants and fundraising, but an additional EUR 20–25 million is needed to fully fund the next phase.
Herantis Pharma Oyj Annual report: H2 2025
Herantis Pharma Oyj has published its H2 2025 annual report on March 5, 2026.
Herantis Pharma Oyj Quarterly report: H2 2025
Herantis Pharma Oyj has published its H2 2025 quarterly earnings report on March 5, 2026.
Herantis Pharma Oyj Slides: H2 2025
Herantis Pharma Oyj has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 5, 2026.
Herantis Pharma Oyj Slides: Company presentation
Herantis Pharma Oyj has posted slides in relation to its latest quarterly earnings report, which was published on January 23, 2026.
Herantis Pharma Oyj Phase 1b Biomarker Data Transcript
Herantis Pharma Oyj Phase 1b Biomarker Data Transcript
Herantis Pharma Oyj Transcript: Study Result
HER-096 demonstrated clear biological activity in Parkinson's patients, with dose-dependent effects on proteostasis, mitochondrial function, and oxidative stress pathways. These biomarker findings support the drug's mechanism, reduce risk for Phase 2, and strengthen partnering prospects.
Herantis Pharma Oyj Press release: Study Result
Herantis Pharma Oyj issued a press release on January 8, 2026, disclosing material business information to investors.
Herantis Pharma Oyj Transcript: Study Result
HER-096 phase I-B trial in Parkinson's patients met safety and PK endpoints, with most adverse events being mild injection site reactions and no drug-related serious events. PK data support twice-weekly dosing, and biomarker analysis is ongoing to inform phase II design and partnering.
Herantis Pharma Oyj Press release: Study Result
Herantis Pharma Oyj issued a press release on October 8, 2025, disclosing material business information to investors.